Literature DB >> 31189630

Quality of warfarin management in primary care: Determining the stability of international normalized ratios using a nationally representative prospective cohort.

Sharon Liu1, Alexander Singer2, Finlay A McAlister3, William Peeler4, Balraj S Heran5, Neil Drummond6, Donna P Manca7, G Michael Allan8, Christina Korownyk9, Michael R Kolber10, Michelle Greiver11, Scott R Garrison12.   

Abstract

OBJECTIVE: To determine the stability of warfarin anticoagulation using a nationally representative sample of Canadian primary care patients and providers.
DESIGN: Prospective cohort study.
SETTING: Primary care practices associated with the Canadian Primary Care Sentinel Surveillance Network. PARTICIPANTS: Adult warfarin users with 7 or more evaluable international normalized ratio (INR) readings. MAIN OUTCOMES MEASURES: International normalized ratio time in therapeutic range (TTR) determined using the Rosendaal method; TTR above 75% was considered good INR control and TTR below 60% was considered poor INR control. The primary outcome was the proportion of all warfarin users (using an INR target range of 2.0 to 3.5) with good INR control during their first year taking warfarin who have poor INR control the following year. Secondary outcomes included the TTR using an INR target of 2.0 to 3.0 when restricted to patients with known atrial fibrillation (AF) or venous thromboembolism (VTE); and the proportion of INR values below the target of 2.0 and above the targets of 3.0 and 3.5 in the year before the availability of other oral anticoagulants.
RESULTS: Among 18 303 adult warfarin users (mean age of 71.0 years, 46.6% female), the median TTR (INR target range of 2.0 to 3.5) was 77.4% (interquartile range of 64.6% to 86.4%). The TTR was above 75% in 56.0% of patients and below 60% in 19.3% of patients. Of those exhibiting good INR control in year 1 of anticoagulation therapy, only 10.2% had poor control the following year. When restricted to patients with known AF or VTE (89.7% with AF and 13.5% with VTE), and assuming an INR target range of 2.0 to 3.0, the TTR was 67.8% (interquartile range of 54.8% to 77.9%). Of these patients, 27.9% had INR values below 2.0, and 19.4% and 8.6% had values above 3.0 and 3.5, respectively.
CONCLUSION: Primary care warfarin management produces a TTR comparable to that in randomized trials, with out-of-range INR values 3 times more likely to predispose to thrombosis (INR of < 2.0) than to hemorrhage (INR of > 3.5). A history of good INR control does predict future INR stability and meaningfully informs decisions to switch established warfarin users onto newer agents. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31189630      PMCID: PMC6738378     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  27 in total

1.  Building a pan-Canadian primary care sentinel surveillance network: initial development and moving forward.

Authors:  Richard Birtwhistle; Karim Keshavjee; Anita Lambert-Lanning; Marshall Godwin; Michelle Greiver; Donna Manca; Claudia Lagacé
Journal:  J Am Board Fam Med       Date:  2009 Jul-Aug       Impact factor: 2.657

Review 2.  Effect of study setting on anticoagulation control: a systematic review and metaregression.

Authors:  Carl van Walraven; Alison Jennings; Natalie Oake; Dean Fergusson; Alan J Forster
Journal:  Chest       Date:  2006-05       Impact factor: 9.410

3.  Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.

Authors:  Harvey D White; Michael Gruber; Jan Feyzi; Scott Kaatz; Hung-Fat Tse; Steen Husted; Gregory W Albers
Journal:  Arch Intern Med       Date:  2007-02-12

4.  The quality of routine oral anticoagulant therapy in a large geographical area. A survey of 310,300 inhabitants.

Authors:  Tomas Holm; Jens F Lassen; Steen E Husted; Lene Heickendorff
Journal:  Dan Med Bull       Date:  2002-08

Review 5.  Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials.

Authors:  G W Albers; D G Sherman; D R Gress; J E Paulseth; P Petersen
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

6.  Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial.

Authors:  David B Matchar; Gregory P Samsa; Stuart J Cohen; Eugene Z Oddone; Annette E Jurgelski
Journal:  Am J Med       Date:  2002-07       Impact factor: 4.965

7.  Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial.

Authors:  Lyne Lalonde; Josée Martineau; Normand Blais; Martine Montigny; Jeffrey Ginsberg; Martine Fournier; Djamal Berbiche; Marie-Claude Vanier; Lucie Blais; Sylvie Perreault; Isabel Rodrigues
Journal:  Am Heart J       Date:  2008-06-03       Impact factor: 4.749

8.  Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.

Authors:  Elaine M Hylek; Alan S Go; Yuchiao Chang; Nancy G Jensvold; Lori E Henault; Joe V Selby; Daniel E Singer
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

9.  Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: a meta-analysis.

Authors:  Deborah A Cios; William L Baker; Stephen D Sander; Olivia J Phung; Craig I Coleman
Journal:  Am J Health Syst Pharm       Date:  2009-05-15       Impact factor: 2.637

10.  Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial.

Authors:  S Jo-Anne Wilson; Philip S Wells; Michael J Kovacs; Geoffrey M Lewis; Janet Martin; Erica Burton; David R Anderson
Journal:  CMAJ       Date:  2003-08-19       Impact factor: 8.262

View more
  6 in total

1.  Quality of warfarin management.

Authors:  Murray Blakes Trusler
Journal:  Can Fam Physician       Date:  2019-08       Impact factor: 3.275

2.  Warfarin management in primary care.

Authors:  Deanna Telner; Jennifer Lake; Gursharan Soor; Jennifer Rossiter; Babak Aliarzadeh
Journal:  Can Fam Physician       Date:  2019-08       Impact factor: 3.275

3.  The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial.

Authors:  Scott R Garrison; Lee Green; Michael R Kolber; Christina S Korownyk; Nicole M Olivier; Balraj S Heran; Mary E Flesher; G Michael Allan
Journal:  Ann Fam Med       Date:  2020-01       Impact factor: 5.166

4.  Cost of incorrect application of antithrombotic prophylaxis prior to invasive procedures.

Authors:  Ma Victoria Cuevas; Ignacio Martínez-Sancho; Jana Arribas; Covadonga García-Díaz; Beatriz Cuevas
Journal:  BMC Health Serv Res       Date:  2019-11-06       Impact factor: 2.655

Review 5.  Magnitudes of Risk Factors of Venous Thromboembolism and Quality of Anticoagulant Therapy in Ethiopia: A Systematic Review.

Authors:  Bekalu Kebede; Tirsit Ketsela
Journal:  Vasc Health Risk Manag       Date:  2022-04-11

6.  Warfarin anticoagulation in the Covid-19 pandemic: Telephone-based management at a regional hematology outpatient center in Joinville, Brazil.

Authors:  Kendra Lys Calixto Machado; Suzana Tanquella da Rosa; Soraya Dobner; Ivan Schneider Boettcher; Gilberto Comaru Pasqualotto; Adelina Elisabeth Lehmkuhl Lopes; Tainá de Araújo; Lysandra Patricia Luchtenberg Bolduan; Maria Daniela Holthausen Perico Colombo; Marcelo Pitombeira de Lacerda
Journal:  Thromb Res       Date:  2021-07-09       Impact factor: 3.944

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.